Evaluation of toxic effects of chemotherapy in lung malignancies on cerebral white matter using diffusion tensor imaging

Figure 1

Fractional anisotropy (FA), axial diffusivity (AD), mean diffusivity (MD) and radial diffusivity (RD) values of the defined regions of interest in the patients with non-small cell lung cancer (NSCLC) and the control group

Regions of interest	NSCLC patients (n = 25)				Control (n = 27)
	FA	AD	MD	RD	FA	AD	MD	RD
R ILF	591.86±74.62	1500.75±122.17	863.76±65.15	545.27±96.29	575.66±79.55	1458.45±131.20	843.76±76.46	536.41±93.74
L ILF	600.06±59.94	1529.15±173.76	868.6±97.02	538.32±103.53	613.26±80.83	1543.02±136.96	856.6±105.47	513.38±125.10
R SLF	558.53±114.37	1299.28±201.73	754.18±67.60	481.63±88.42	595.02±87.69	1411.18±141.51	792.77±46.74	483.57±74.45
L SLF	532.01±118.55	1299.01±173.29	778.50±71.55	518.24±110.51	591.15±96.81	1416±149.16	795.97±59.44	485.95±82.96
R FM	554.53±100.65	1338.19±156.48	769.57±105.53	512.13±99.98	629.28±151.29	1508.51±288.33	813.40±80.35	465.84±139.28
L FM	507.28±109.36	1307.52±188.16	807.18±63.09	557.02±109.36	653.10±173.43	1605.51±322.02	836.1±86.54	451.52±168.22
R ATR	340.74±88.42	1103.33±81.11	808.82±52.68	661.56±75.32	356.29±93.06	1079.83±101.61	785.80±60.54	638.79±74.98
L ATR	346.5±80.36	1106.73±129.93	787.19±107.16	654.76±99.75	370.34±99.10	1106.84±127.16	795.80±78.49	640.28±91.63
R ACR	462.64±165.21	1257.80±260.67	796.58±212.71	593.33±239.64	474.52±112.45	1189.22±123.22	766.57±64.26	555.24±93.58
L ACR	426.54±118.96	1132.28±137.42	771.2±75.36	590.67±106.29	493.42±113.02	1204.54±150.69	762.29±68.51	541.17±86
R EC	421.5±103.19	1186.76±131.98	801.44±49.57	608.78±75.25	467.90±76.67	1206.38±142.25	785.90±67.27	575.67±66.99
L EC	473.82±92.65	1207.59±112.50	775.09±67.91	558.84±93.05	496.03±82.19	1220.38±150.32	766.20±69.01	539.11±75.26
R IFOF	492.68±71.61	1265.71±107.18	790.68±68.32	553.16±80.63	518.93±69.64	1319.51±149.14	803.93±64.48	546.14±61.75
L IFOF	475.18±85.00	1235.06±108.44	786.80±56.69	562.67±77.186	492.90±88.55	1305.21±143.83	817.78±68.26	574.07±80.16
G CC	805.78±79.27	1773.6±231.49	799.20±135.38	312±138.14	792.98±56.11	1810.47±167.43	822.28±72.58	328.19±75.54
S CC	806.87±83.00	1862.29±206.96	832.26±115.01	317.24±143.53	845.36±49.03	1823.75±243.74	775.42±113.42	251.25±81.05
R FWM	383.34±89.30	1171.85±148.03	822.22±66.41	647.41±81.58	388.92±109.23	1137.18±106.56	798.74±61.26	629.51±98.77
L FWM	377.06±89.53	1143.71±126.45	810.22±55.30	643.47±69.93	399.48±116.43	1147.24±114.15	798.29±78.91	623.81±114.37
R POWM	353.36±76.49	1155.84±130.45	837.16±70.62	677.82±70.49	394.78±91.19	1182.94±193.23	818.38±108.45	636.1±103.87
L POWM	344.49±75.64	1142.25±122.83	834.81±74.07	681.09±75.55	388.00±89.02	1254.38±148.62	871.37±93.75	679.86±102.15

Comparison of diffusion tensor imaging (DTI) values of the defined anatomic locations before and after chemotherapy (the significant results are in italics)

Group 1 (n:7)				Group 2 (n:18)
Region of interest	Pre-chemotherapy values (Median (min-max))	Post-chemotherapy values (Median (min-max))	P value	Regions of interest	Pre-chemotherapy values (Median (min-max)	Post-chemotherapy values (Median (min-max)	P value
R ILF FA	623 (514–703.3)	522 (418.7–679.8)	0.028	R ILF FA	600 (395.3–694.5)	593 (336–707)	0.89
R FM FA	539 (448–591)	471 (379.7–615.8)	0.31	R FM FA	525 (454.5–864)	487 (322.3–712)	0.022
R FM RD	487.4 (465.5–605.65)	619.4 (439.5–667.85)	0.062	R FM RD	533.275 (201–689)	580.35 (367.8–819.15)	0.011
R FWM AD	1123.5 (912.8–1244)	1135.5 (988.3–1265.5)	0.39	R FWM AD	1157.65 (1011.3–1556.5)	1104.15 (854.8–1256.3)	0.008
R FWM MD	786.1 (699.1–871.26)	823.26 (658.93–855.1)	0.31	R FWM MD	793.01 (658.2–955.36)	812.33(704.53–1006.9)	0.029

Comparison of the diffusion tensor imaging (DTI) results of the two chemotherapy regimens on the defined anatomic locations (only the significant results are shown)

Region of interest	Cisplatin	Carboplatin	P
Left POWM FA	389 (273.3–531)	319 (167.3–423)	0.034
Left POWM MD	767.6 (727.53–925.27)	837.13 (737.2–1071.77)	0.034
Left POWM RD	606.1 (507.9–726.65)	705.92 (592.80–905.15)	0.029